Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 16/20 | 0.83 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.83 |
| ▸ | PDE2A | O00408 | 4/20 | 0.45 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.41 |
| ▸ | PTGFR | P43088 | 1/20 | 0.41 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13210500 | 0.91 | PTGER4 (0.86) | PTGER4PTGER2PDE2APTGDRTBXA2R | |
| SCHEMBL2351863 | 0.91 | PTGER4 (1.00) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| SCHEMBL4085052 | 0.90 | PTGER4 (0.98) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| SCHEMBL3019807 | 0.90 | PTGER4 (0.75) | PTGER4PTGER2PDE2APTGDRTBXA2R | |
| SCHEMBL4085048 | 0.89 | PTGER4 (0.83) | PTGER4PTGER2PDE2APTGDRTBXA2R | |
| Diethylamine SCHEMBL3019803 | 0.86 | PTGER4 (0.91) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| SCHEMBL28263352 | 0.85 | PTGER4 (0.74) | PTGER4PTGER2PDE2APTGDRTBXA2R | |
| SCHEMBL4085074 | 0.85 | PTGER4 (0.77) | PTGER4PTGER2PDE2APTGDRTBXA2R | |
| SCHEMBL14301888 | 0.84 | PTGER4 (0.75) | PTGER4PTGER2PDE2APTGDRTBXA2R | |
| Formic Acid SCHEMBL28263353 | 0.84 | PTGER4 (0.78) | PTGER4PTGER2PDE2APTGDRTBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969394-B2 | Thiophenecarboxamide derivatives as EP4 receptor ligands | MERCK FROSST CANADA LTD. (CA) | 2015-03-03 | — | — | US | disclosed |
| US-8969394-B2 | Thiophenecarboxamide derivatives as EP4 receptor ligands | MERCK FROSST CANADA LTD. (CA) | 2015-03-03 | — | — | US | disclosed |
| US-8969394-B2 | Thiophenecarboxamide derivatives as EP4 receptor ligands | MERCK FROSST CANADA LTD. (CA) | 2015-03-03 | — | — | US | disclosed |
| EP-2054401-B1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK CANADA INC (CA) | 2013-05-01 | — | — | EP | disclosed |
| EP-2054401-B1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK CANADA INC (CA) | 2013-05-01 | — | — | EP | disclosed |
| US-20100204487-A1 | PROCESS FOR MAKING THIOPHENE CARBOXAMIDE DERIVATIVES | DAVIES IAN | 2010-08-12 | — | — | US | disclosed |
| US-20100204487-A1 | PROCESS FOR MAKING THIOPHENE CARBOXAMIDE DERIVATIVES | DAVIES IAN | 2010-08-12 | — | — | US | disclosed |
| US-20090247596-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK CANADA INC. (CA) | 2009-10-01 | — | — | US | disclosed |
| US-20090247596-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK CANADA INC. (CA) | 2009-10-01 | — | — | US | disclosed |
| US-20090247596-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK CANADA INC. (CA) | 2009-10-01 | — | — | US | disclosed |
| EP-2054401-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | Merck Frosst Canada Ltd. (CA) | 2009-05-06 | — | — | EP | disclosed |
| WO-2009020588-A1 | PROCESS FOR MAKING THIOPHENE CARBOXAMIDE DERIVATIVE | MERCK & CO., INC. (US) | 2009-02-12 | — | — | WO | disclosed |
| WO-2008017164-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK FROSST CANADA LTD. (CA) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008017164-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK FROSST CANADA LTD. (CA) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204487-A1 | PROCESS FOR MAKING THIOPHENE CARBOXAMIDE DERIVATIVES | PTGER4, P2RY4, PTGES2 | PTGER4 1/4885PTGER2 7/4885PDE2A 1214/4885 |
| US-20090247596-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER2 3/4885PDE2A 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.